Eliquis Regulatory Post Marketing Surveillance


Phase N/A Results N/A

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria

- Patients ≥19 years of age
- Adult patients who are diagnosed with nonvalvular atrial fibrillation and are initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic embolism
- Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion Criteria

- Receiving Eliquis treatment for an indication that is not approved in Korea
- Contraindicated for the use of Eliquis as described in the Korean label